Home・Stock List・Xencor Inc

Xencor Inc

Closed

SectorHealthcare

23.21 1.49

Buy Sell

Overview

Share price change

24h

Current

Min

22.48

Max

23.41

Key metrics
By Trading Economics
Income	-22M -151M
Sales	47M 51M
EPS	-0.29
Profit margin	-294.108
Employees	260
EBITDA	109M -12M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+31.75% upside

Dividends
By Acuity
Next Earnings	3 Nov 2026

Market Stats
By TradingEconomics
Market Cap	166M 1.6B
Previous open	21.72
Previous close	23.21

Xencor Inc Chart

Past performance is not a reliable indicator of future results.

Related News

14 Aug 2026, 19:16 UTC

Shares of Xencor Inc. are modestly higher amid cautious broader market sentiment following a decline in U.S. retail sales for July.

13 Aug 2026, 19:21 UTC

Xencor Inc shares are lower today, with no specific news driving the decline. High trading volume suggests increased activity amid routine fluctuations.

12 Aug 2026, 19:56 UTC

Social Media

Xencor Inc shares are higher, supported by social media discussions valuing the company at $1.3 billion based on its ENPP3 asset potential.

11 Aug 2026, 19:26 UTC

Xencor Inc shares are advancing, continuing a four-session trend. Investors are focused on upcoming inflation reports that may influence market sentiment.

10 Aug 2026, 19:31 UTC

News

Xencor Inc shares are higher today, buoyed by increased institutional investments from Dimensional Fund Advisors and BVF Inc. IL.

7 Aug 2026, 23:16 UTC

Xencor Inc shares are higher in after-market trading, supported by decreased interest rate hike expectations following a Labor Department report on non-farm payrolls.

6 Aug 2026, 20:03 UTC

News

Xencor shares are higher as Cantor Fitzgerald raises its price target to $44, reflecting confidence in the company's pipeline and upcoming ESMO Congress presentation.

3 Aug 2026, 19:51 UTC

Xencor Inc's shares are declining, continuing a downward trend since Friday's close, despite a broader market rally in technology and airlines.

31 Jul 2026, 20:03 UTC

Xencor Inc shares are lower, reversing earlier gains amid rising US Treasury yields and crude oil prices, contributing to inflation concerns and interest rate expectations.

30 Jul 2026, 19:03 UTC

News

Social Media

Xencor Inc. gains following a $105 million settlement with Alexion, boosting investor confidence and extending its operating runway through 2028.

29 Jul 2026, 19:36 UTC

Xencor Inc. shares are lower as broader market trends decline ahead of the Federal Reserve's policy announcement, amid rising oil prices and inflation concerns.

28 Jul 2026, 20:07 UTC

Xencor Inc is gaining amid a strong Biotechnology sector, despite earlier declines. The stock has rebounded to settle near the upper end of its one-month range.

27 Jul 2026, 19:11 UTC

Xencor Inc shares are higher today, reflecting a positive market environment despite earlier intraday pullbacks. No specific news was identified to explain the movement.

24 Jul 2026, 19:11 UTC

Xencor Inc shares are lower in Friday's session, reflecting broader market trends. No specific news was identified to explain the price movement.

22 Jul 2026, 20:06 UTC

Xencor Inc shares are lower today, retracing from an earlier peak. Broader market sentiment is affected by uncertainty ahead of the Federal Reserve meeting.

21 Jul 2026, 19:02 UTC

Social Media

Xencor Inc. shares reached a new 52-week high, driven by developments in RCC related to ENPP3 and immuno-oncology efforts involving TL1A.

20 Jul 2026, 19:41 UTC

Social Media

Xencor Inc's shares are higher as clinical results are accepted for presentation at the ESMO conference, with a Phase 3 trial planned for 2027.

Peer Comparison

Price change

Xencor Inc Forecast

Price Target

By TipRanks

31.75% upside

12 Months Forecast

Average 30.29 USD 31.75%

High 44 USD

Low 20 USD

Based on 10 Wall Street analysts offering 12 month price targets forXencor Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to Xencor Inc - Dist in the past 3 months.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.